Our Products

Health Shape Patient Care Worldwide

As a leading innovation-driven organisation, Lilly is developing a growing portfolio of pharmaceutical products focused on meeting some of the world's most urgent medical needs in the fields of cardiovascular disease, diabetes, endocrine, musculoskeletal disease, neuroscience, oncology and urology.

 

Cardiovascular

Adcirca® (tadalafil)***

Efient® (prasugrel)*

ReoPro® (abciximab)**

 

Diabetes

Humalog® (human insulin analogue)

Humulin® (human insulin)

Trajenta® (linagliptin)**

Jentadueto® (metformin hydrochloride, linagliptin)**

 

Endocrine

Humatrope® (somatropin)

 

Musculoskeletal

Forsteo® (teriparatide)

 

Neuroscience

Amyvid™ (florbetapir 18F)

Cymbalta® (duloxetine)

Strattera® (atomoxetine)

Zyprexa® (olanzapine)

Zypadhera® (olanzapine pamoate monohydrate)

Prozac® (fluoxetine hydrochloride)

 

Oncology

Alimta® (pemetrexed)

Gemzar® (gemcitabine hydrochloride)

 

Urology

Cialis® (tadalafil)

Yentreve® (duloxetine)

 

* Lilly is the marketing authorisation holder (MAH) but either co promotes or co markets this product

** Lilly is not the marketing authorisation holder (MAH) but either promotes, markets or distributes this product

*** Lilly is the marketing authorisation holder (MAH) but does not promote this product